The Beauty Health (SKIN) Intrinsic Value Calculator

Updated: Nov 16, 2026

The Beauty Health (SKIN) trades at $15.05, below its base-case intrinsic value of $32.50 — an implied 116% margin of safety. The model starts from $4.48 in expected earnings per share, grows it at 25.0% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 6.0x exit multiple, and discounts the result back at 10% per year. The discount suggests the market expects slower growth or a lower multiple than the base case; use the sliders below to stress-test how much growth deterioration the current price already absorbs.

Undervalued by 116.0%
Current Price
$15.05
Intrinsic Value
$32.50
Implied Upside: +116.0%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 25.0%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 6.0x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$32.50
--
Tradestie Long-Horizon Cycle Intelligence (2019–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (7-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Surgical & Medical Instruments & Apparatus • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Surgical & Medical Instruments & Apparatus, only 29.8% of peer companies at all-scale revenue scale (1321 historical 5-year windows; industry median CAGR: 8.4%/yr) sustained ≥15%/yr 5-year compound revenue growth (broad all-scale equity base rate: 26.2%).

≥5%/yr (5Y)
64.9%
All all-scale: 57.1%
≥10%/yr (5Y)
44.3%
All all-scale: 37.8%
≥15%/yr (5Y)
29.8%
All all-scale: 26.2%
≥20%/yr (5Y)
21.4%
All all-scale: 19.3%
≥25%/yr (5Y)
15.0%
All all-scale: 14.6%
≥30%/yr (5Y)
11.7%
All all-scale: 11.3%
7-Yr Revenue Scale
$167M → $301M
6Y CAGR: +10.3%/yr • 5Y: +20.4%
2008–2009 Cycle Trough Floor
Post-2009 Series
Tracked from FY2019
2022 Rate-Shock Floor
-32.9% Op Margin
FY2023 Rev: $398M (+8.8% YoY)
Latest vs Cycle Median Margin
-6.9% vs -14.4% med
Cyclical Margin Profile — Stress-Test Exit Multiples
Multi-Cycle Revenue & Operating Margin Trajectory (2019–2025) Expansion 2008–09 / 2022 Macro Stress
8%
'19
-14%
'20
-15%
'21
-7%
'22
-33%
'23
-20%
'24
-7%
'25
Inspect All 7 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $301M -10.0% -$21M -6.9% Standard
FY2024 (2024-12) $334M -16.0% -$68M -20.3% Standard
FY2023 (2023-12) $398M +8.8% -$131M -32.9% 2022–23 Shock Floor
FY2022 (2022-12) $366M +40.7% -$26M -7.1% 2022 Rate Shock
FY2021 (2021-12) $260M +118.4% -$40M -15.4% Standard
FY2020 (2020-12) $119M -28.5% -$17M -14.4% Standard
FY2019 (2019-12) $167M — $13M 8.1% Standard

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

Model Inputs
Base EPS $4.48
Current Price $15.05
Historical PE 6.0x
Analyst Growth Est. 25.0%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).